evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

68 questions · 72 findings · 36 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 9.7%GRADE not reported 2 · 2.8%Very low 22 · 30.6%Low 22 · 30.6%Moderate 13 · 18.1%High 6 · 8.3%

Cells vs no cells

All‐cause mortality ‐ long‐term · Anyone diagnosed with AMI

Cells showed no clear difference in all‐cause mortality ‐ long‐term compared with no cells (moderate certainty).

1 finding from 1 review

Pulmonary artery perfusion with blood vs no perfusion during cardiopulmonary bypass

Mortality within the longest · adult surgical patients with the need for cardiopulmonary bypass‐dependent heart surgery

It is very uncertain whether pulmonary artery perfusion with blood changes all‐cause mortality within longest compared with no perfusion during cardiopulmonary bypass (very low certainty).

1 finding from 1 review

Perioperative restrictive fluid therapy vs goal‐directed fluid therapy

Mortality within the longest · adults receiving intravenous fluids while undergoing major non‐cardiac surgery

It is very uncertain whether perioperative restrictive fluid therapy changes all‐cause mortality (during longest compared with goal‐directed fluid therapy (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Omega‐3 fatty acids and antioxidants vs standard diet or placebo

Mortality within the longest · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…

Omega‐3 fatty acids and antioxidants showed no clear difference in all‐cause mortality (longest period reported) compared with placebo or standard nutrition (low certainty).

1 finding from 1 review

Levosimendan vs placebo

All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome

It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).

1 finding from 1 review

Levosimendan vs dobutamine

All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).

1 finding from 1 review

Complete revascularisation vs culprit‐only revascularisation

Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.

It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).

1 finding from 1 review

self‐management of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring or self‐management of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term mortality (binary outcome) All‐cause mortality for the… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).

2 findings from 1 review

Prophylactic corticosteroids vs placebo or no corticosteroids

Mortality within the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass

Prophylactic corticosteroids showed no clear difference in all‐cause mortality (during the index hospital admission, or within… compared with placebo or no corticosteroids (low certainty).

1 finding from 1 review

Intravenous tranexamic acid vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review